Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O0QB
|
|||
| Former ID |
DIB008414
|
|||
| Drug Name |
ATG-Fresenius S
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Transplant rejection [ICD-11: NE84; ICD-9: 279.5, 996] | Phase 3 | [1] | |
| Company |
Enzon
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cells (T-cells) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00655343) Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Neovii Biotech. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.